...Sandra Philipp Zusammenfassung Die Studie untersucht, wie sich eine nicht chirurgische Behandlung von Parodontitis im Vergleich zu herkömmlichen dermatologischen Methoden auf die Schwere und das Ausmaß der Psoriasis bei Patienten auswirkt, die unter beiden Krankheiten leiden. Insgesamt wurden dafür...

...Uwe Wollina Introduction: Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement...

...Felix Lauffer Background: Effective, well-tolerated oral psoriasis treatments are needed. Objective: To compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, versus placebo and apremilast in adults with moderate to severe plaque psoriasis...

...Sandra Philipp Risankizumab, a humanized immunoglobin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit, is approved in Japan to treat numerous indications, including generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). Both GPP and EP...

...Martina Burlando; Ilaria Salvi; Andrea Paravisi; Emanuele Cozzani; Aurora Parodi Die generalisierte pustuläre Psoriasis (GPP) ist eine schwere und potenziell lebensbedrohliche Art der Psoriasis. Wir stellen den Fall eines Patienten mit schwerer GPP vor, die zunächst erfolglos mit Cyclosporin...

...Piyu Parth Naik Zusammenfassung Hintergrund: Psoriasis ist eine immunvermittelte, langwierige Erkrankung, von der weltweit etwa 100 Millionen Menschen betroffen sind. Anti-Interleukin (IL)-23-Wirkstoffe haben einen besonderen Status in Bezug auf die Sicherheit und klinische Wirksamkeit. Anti-IL-23...

...Alexander Navarini Generalized pustular psoriasis is a potentially life-threatening neutrophilic skin disease characterized by recurrent flares of widespread erythema and eruption of sterile pustules. In the Effisayil™ 1 study (NCT03782792), 53 patients with a generalized pustular psoriasis flare...

...Percy Lehmann Background: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor licensed for the treatment of type 2 diabetes mellitus (T2DM), has been reported to improve psoriasis. Objective: We compared the effects of sitagliptin treatment, a DPP-4 inhibitor, in combination with narrow-band...

...Regina Fölster-Holst Psoriasis is a chronic inflammatory systemic disease primarily affecting the skin, but which often involves considerable comorbidities as well. One-third of psoriasis cases start during childhood. In pediatric psoriasis, an association with several medical comorbidities is also...

...Michael Sticherling Introduction: Secukinumab, a fully human monoclonal antibody that directly inhibits interleukin-17A, has demonstrated robust efficacy in the treatment of moderate to severe psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a rapid onset of action...

...Markus Braun-Falco Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed...

...Masahiro Kamata; Tada Yayoi Zusammenfassung Die Psoriasis ist eine chronisch entzündliche Hauterkrankung, die durch ein schuppiges, induriertes Erythem gekennzeichnet ist und erhebliche Auswirkungen auf die Lebensqualität der Patienten hat. Sie ist nicht nur als Hautkrankheit, sondern als...

...Wiebke Sondermann Background: Real-world studies evaluating patients with challenging-to-treat localizations of psoriasis (scalp, nail, and palmoplantar) are limited. Objective: To characterize patients with versus without psoriasis in challenging-to-treat areas seen in routine US clinical practice...

...Sandra Philipp Background: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported. Methods: This retrospective observational multicenter study aimed to describe efficacy...

...Natalia Kirsten Objective: Psoriasis and depression may have common mechanisms, such as systemic inflammation, dysfunction of the hypothalamic-pituitary-adrenal axis, and vitamin D3 deficiency. Among men with psoriasis, this study examined whether depression severity was associated with serum...

...Wiebke Sondermann Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 psoriasis patients who received 6 months of etanercept treatment were consecutively...

...Uwe Gieler Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 psoriasis patients who received 6 months of etanercept treatment were consecutively...

...Sandra Philipp The prevalence of affective disorders such as depression and anxiety is particularly high in patients with autoimmune diseases, including inflammatory skin diseases such as psoriasis, atopic dermatitis, and hidradenitis suppurativa. A dysregulated immune response has been linked...

...Percy Lehmann Background: The prevalence of narrow-band ultraviolet B (NB-UVB) use in Europe for moderate and severe psoriasis is unknown, because national registries for psoriasis do not monitor this treatment. Objectives: To quantify the use of phototherapy, biologics or conventional treatments...

... with specific focus on its role in certain inflammatory skin conditions such as psoriasis and atopic dermatitis. Methods: A comprehensive literature search was carried out in PubMed and Google Scholar databases using keywords like “vitamin D,” “skin,” “atopic dermatitis,” and “psoriasis.” Only articles...